Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF C	HANGES	IN BEN	IEFICIAL	OWNER	SHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Francois Cedric					2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [ APLS ]								Relationship of eck all applice X Director	or 10% (				
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC 6400 WESTWIND WAY, SUITE A				3. Date of Earliest Transaction (Month/Day/Year) 08/23/2019								X Officer (give title Other (specify below)  Chief Executive Officer						
(Street) CRESTV (City)			40014 (Zip)		4.1	f Ame	ndme	nt, Date (	of Origina	l Filed	d (Month/Da	ay/Year)	Line	X Form fi	led by Or	ne Repo	g (Check A orting Pers n One Rep	on
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			action	tion 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)  4. Securities A Disposed Of (I			es Acquire	d (A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			/2019			Code	v	Amount 37,505	(A) or (D)	Price \$2.67	Transactio (Instr. 3 ar	on(s) and 4)		(11341.4)				
Common Stock  Common Stock			72013	.015		IVI		37,303	A	Ψ2.07	234,411				See Footnote <sup>(1)</sup>			
			Table II -								osed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)		3A. Deem Execution if any (Month/Da	on Date, Trai		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to	\$2.67	08/23/2019			M			37,505	(2)		12/04/2023	Common Stock	37,505	\$0	478,2	200	D	

## **Explanation of Responses:**

- 1. The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
- 2. This option was granted on December 5, 2013 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

/s/ David Watson, attorney-infact for Cedric Francois

08/26/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.